Aflibercept Stocks List
Related Industries: Biotechnology
Related Stock Lists:
Angiogenesis
Antibodies
Asthma
Atopic Dermatitis
Biopharmaceutical
Biotechnology
Bone
Breakthrough Therapy
Cardiovascular Disease
Cartilage
Cholesterol
Clinical Development
Clinical Research
Colorectal Cancer
Dermatitis
Disorders
Human Monoclonal Antibodies
Immune Diseases
Immunology
Infectious Diseases
Symbol | Grade | Name | Weight | |
---|---|---|---|---|
IBB | D | iShares Nasdaq Biotechnology Index Fund | 8.09 | |
IBBQ | D | Invesco Nasdaq Biotechnology ETF | 8.07 | |
BBH | D | Market Vectors Biotech ETF | 7.74 | |
BIB | D | ProShares Ultra Nasdaq Biotechnology | 5.95 | |
PJP | C | PowerShares Dynamic Pharmaceuticals | 5.72 |
Compare ETFs
Related Industries:
Biotechnology
Related Stock Lists:
Angiogenesis
Antibodies
Asthma
Atopic Dermatitis
Biopharmaceutical
Biotechnology
Bone
Breakthrough Therapy
Cardiovascular Disease
Cartilage
Cholesterol
Clinical Development
Clinical Research
Colorectal Cancer
Dermatitis
Disorders
Human Monoclonal Antibodies
Immune Diseases
Immunology
Infectious Diseases
- Aflibercept
Aflibercept is a biopharmaceutical drug invented by Regeneron Pharmaceuticals, approved in the United States and Europe for the treatment of wet macular degeneration under the trade name Eylea, and for metastatic colorectal cancer as Zaltrap. As the active ingredient of Zaltrap, the substance is called ziv-aflibercept in the US.
It is an inhibitor of vascular endothelial growth factor (VEGF).Aflibercept is being co-developed for cancer treatment by Sanofi and Regeneron under a deal signed in 2003, and is being co-developed for eye diseases by Bayer HealthCare and Regeneron under a deal signed in 2006.
Recent Comments
- TraderMike on IZM
- TraderMike on Today's Outage
- Crunching_The_Market on Today's Outage
- TraderMike on Market Recap for Friday, March 8, 2024
- Don_Marat on Market Recap for Friday, March 8, 2024
From the Blog
Featured Articles